Physician profile
Hanh Bui
NPI 1275519175
$28,644.82
in general payments reported to CMS, 2019-2025
50 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,299 · 2020: $2,204 · 2021: $2,278 · 2022: $1,625 · 2023: $6,537 · 2024: $1,466 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $6,385 · Travel and Lodging: $3,633 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,125.00 |
| Food and Beverage | $6,385.01 |
| Travel and Lodging | $3,633.48 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $9,622.95 | 2022-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $3,793.57 | 2019-2025 | Leqvio |
| Janssen Research & Development, LLC | $2,508.01 | 2023 | |
| Boston Scientific Corporation | $1,711.33 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Farapulse, Accolade Sr |
| Abbott Laboratories | $1,544.72 | 2019-2024 | Mitraclip |
| Bayer Healthcare Pharmaceuticals INC. | $1,217.92 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $704.09 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $671.29 | 2019-2025 | Verquvo, Capvaxive |
| Philips North America LLC | $597.07 | 2020-2025 | Extended Holter |
| Pfizer INC. | $553.69 | 2019-2023 | |
| Biotronik INC. | $488.14 | 2019-2024 | Biomonitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.91 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $419.33 | 2019-2022 | |
| Medtronic Vascular, INC. | $417.54 | 2019-2020 | |
| Glaxosmithkline, LLC. | $390.00 | 2020-2025 | Trelegy Ellipta |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $350.46 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $324.29 | 2019-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $312.22 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $300.11 | 2019-2024 | |
| Novo Nordisk INC | $234.16 | 2021-2024 | Rybelsus, Ozempic |
| Bardy Diagnostics, INC. | $217.57 | 2019-2022 | |
| Esperion Therapeutics, INC. | $183.02 | 2020-2025 | Nexletol |
| Cvrx, INC. | $172.75 | 2023-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.81 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $158.31 | 2019-2025 | Farxiga |
| Acera Surgical, INC. | $120.95 | 2022 | |
| Akcea Therapeutics, INC. | $105.18 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $97.57 | 2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $94.41 | 2024 | Arcalyst |
| Medtronic, INC. | $92.73 | 2021-2023 | Micra |
| Amarin Pharma, INC. | $82.93 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $80.00 | 2019 | |
| Baxter Healthcare | $76.63 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Tactile Systems Technology INC | $64.67 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $55.48 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $53.05 | 2024 | |
| Arbor Pharmaceuticals, INC. | $27.93 | 2019-2022 | |
| Edwards Lifesciences Corporation | $25.50 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $25.38 | 2025 | |
| Bridgebio Pharma, INC. | $21.02 | 2025 | Attruby |
| Elutia, INC. | $18.91 | 2020 | |
| W. L. Gore & Associates, INC. | $16.50 | 2020 | |
| Celgene Corporation | $15.38 | 2023 | Camzyos |
| Medtronic Minimed, INC. | $15.27 | 2020 | |
| Amryt Pharma Holdings Ltd | $14.74 | 2021 | |
| Azurity Pharmaceuticals, INC. | $13.33 | 2023 | Edarbi |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanh Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.